Publications by authors named "Stew Kroll"

14Publications

Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study.

J Cardiothorac Vasc Anesth 2020 Aug 7. Epub 2020 Aug 7.

Divisions of General and Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Department of Cardiovascular Surgery, Texas Heart Institute, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jvca.2020.08.001DOI Listing
August 2020

The authors reply.

Crit Care Med 2019 03;47(3):e271-e272

School of Medicine, The University of Melbourne, Melbourne, VIC, Australia La Jolla Pharmaceutical Company, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000003601DOI Listing
March 2019

Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.

J Crit Care 2019 04 8;50:188-194. Epub 2018 Dec 8.

Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Emory University, Atlanta, GA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcrc.2018.12.007DOI Listing
April 2019

Angiotensin II for the Treatment of Vasodilatory Shock.

N Engl J Med 2017 08 21;377(5):419-430. Epub 2017 May 21.

From Anesthesiology Institute, Center for Critical Care and Department of Outcomes Research, Cleveland Clinic, Cleveland (A.K.); the Department of Medicine (Critical Care), University of Ottawa, and the Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa (S.W.E.); Division of Critical Care Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC (X.S.W.); Regions Hospital, St. Paul, MN (K.H.); University of Tennessee College of Medicine, Chattanooga (J.T.); the Division of Nephrology, Baylor University Medical Center, Dallas (H.S.); the Department of Medicine, Emory University School of Medicine, Atlanta (L.W.B.); Inova Medical Center, Falls Church, VA (L.A.); the Department of Internal Medicine, University of California Davis School of Medicine, Sacramento (T.E.A.), the Division of Critical Care, Department of Anesthesiology, University of California Los Angeles, Los Angeles (D.W.B.), and La Jolla Pharmaceutical Company, San Diego (J.J., S.K., L.S.C., G.F.T.) - all in California; the Department of Pulmonary and Critical Care Medicine, Riverside Methodist Hospital, Columbus, OH (C.M.); the Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore (M.T.M.); the Department of Surgery, Sunrise Hospital, Las Vegas (S.C.); Intensive Care Unit, Wellington Hospital, and Medical Research Institute of New Zealand, Wellington, New Zealand (P.J.Y.); the Division of Critical Care, Department of Medicine, Eastern Idaho Regional Medical Center, Idaho Falls (K.K.); the Department of Medicine, Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago (R.G.W.); the Department of Critical Care and Nephrology, King's College London, Guy's and St. Thomas' Hospital, London (M.O.); the Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh (R.M.); the Department of Medicine, Albert Einstein College of Medicine, and the Division of Critical Care Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); John Hunter Hospital, New Lambton Heights, and School of Medicine and Public Health, University of Newcastle, Callaghan, NSW (R.P.), the Department of Intensive Care, Wesley Hospital and Princess Alexandra Hospital, University of Queensland, St Lucia (B.V.), and School of Medicine, University of Melbourne, Parkville (R.B.), and the Intensive Care Unit, the Royal Melbourne Hospital, University of Melbourne (A.M.D.), Melbourne, VIC - all in Australia; the Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care, and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki (J.H.); INSERM UMR 995 LIRIC (Lille Inflammation Research Center), Centre Hospitalier Universitaire Lille, Critical Care Center and University of Lille School of Medicine, Lille, France (R.F.); and the Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (B.T.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1704154DOI Listing
August 2017

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

J Clin Oncol 2015 May 15;33(13):1475-81. Epub 2014 Dec 15.

Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881365PMC
May 2015

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

J Clin Oncol 2014 Oct 2;32(29):3299-306. Epub 2014 Sep 2.

Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.3660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588714PMC
October 2014

Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302.

Dermatol Reports 2011 Oct 1;3(3):e56. Epub 2011 Dec 1.

Threshold Pharmaceuticals, Redwood City, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/dr.2011.e56DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211495PMC
October 2011